Skip to main content
NewslettersWatchlist

Autolus Therapeutics Plc ADR(AUTL-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low4.39
Day High4.84
Open:4.50
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Barchart
Chart of the Day: Autolus Therapeutics - Effective Cancer Treatments
Motley Fool
Why Autolus Therapeutics Stock Is Crashing Today
PR Newswire
R&D Efforts to Improve Optimal Treatments for Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Progressing
Globe Newswire
Correction - Autolus Therapeutics to Report Second Quarter 2022 Financial Results on August 4, 2022
Globe Newswire
Autolus Therapeutics to Report Second Quarter 2022 Financial Results on August 4, 2022
Globe Newswire
Autolus Therapeutics to Participate in William Blair’s Biotech Focus Conference 2022, New York, July 12 – 13, 2022
Globe Newswire
Autolus Therapeutics Presents Clinical Data Updates at the European Hematology Association Congress
Globe Newswire
Autolus to hold Annual General Meeting (AGM) of Shareholders on Tuesday, June 28, 2022
Globe Newswire
Autolus Therapeutics to Participate in the Jefferies Healthcare Conference, being held in New York from June 8 – 10, 2022
Globe Newswire
Autolus Therapeutics to Present Four Clinical Data Updates at the European Hematology Association Congress
Globe Newswire
Autolus Therapeutics Reports First Quarter 2022 Financial Results and Operational Progress
Globe Newswire
Autolus Therapeutics to Present Three Novel Cell Programming Approaches at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting, May 16-19, 2022
Globe Newswire
FDA Grants Regenerative Medicine Advanced Therapy (RMAT) designation to Autolus’ CAR T cell therapy, obe-cel, for the treatment of adult B-ALL
Globe Newswire
Autolus Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Progress
Globe Newswire
Autolus Therapeutics Announces Publication Describing Novel Cell Programming Technology
Globe Newswire
Autolus Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on March 10
Globe Newswire
Autolus Therapeutics announces retirement of chief financial officer and succession plan
Globe Newswire
Autolus Therapeutics to Present at Conferences During January 2022
Globe Newswire
Blackstone Life Sciences to invest up to $250 million in Autolus Therapeutics to develop obe-cel in adult Acute Lymphoblastic Leukemia (ALL) and advance broader platform
Globe Newswire
Autolus Therapeutics to Present New Data at the 63rd ASH Annual Meeting & Exposition
Globe Newswire
Autolus Therapeutics Reports Third Quarter 2021 Financial Results and Operational Progress
Globe Newswire
Autolus Therapeutics to Report Third Quarter 2021 Financial Results and Host Conference Call on November 3
Globe NewsWire
Autolus Therapeutics provides an update on its manufacturing facility in Stevenage, UK
Globe NewsWire
Autolus Therapeutics announces the appointment of John H. Johnson as non-executive chairman of its Board of Directors
Business Wire
Novaremed Expands its Pipeline of Non-opioid Treatment Candidates for Chronic Pain Indications Through Acquisition of Metys Pharmaceuticals
Globe NewsWire
Autolus Therapeutics to participate in upcoming virtual investor conferences
Globe NewsWire
Autolus Therapeutics announces publication of obe-cel (AUTO1) Phase 1 ALLCAR19 data in adults with relapsed/ refractory B-ALL in Journal of Clinical Oncology
Globe NewsWire
Autolus Therapeutics Announces Promising Innovative Medicine (PIM) designation for obe-cel for the treatment of relapsed/refractory adult B-cell ALL
Globe NewsWire
Autolus Therapeutics Reports Second Quarter 2021 Financial Results and Operational Progress
Globe NewsWire
Autolus and Moderna sign Option and License Agreement for access to proprietary targeting technology from Autolus
Globe NewsWire
Autolus Announces Appointment of Edgar Braendle, M.D., Ph.D., as Chief Development Officer
Globe NewsWire
Autolus Therapeutics to Report Second Quarter 2021 Financial Results on August 5, 2021, and will Participate in the William Blair Biotech Focus Conference 2021 on July 14, 2021

Profile

Autolus Therapeutics plc is a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies. The company's pipeline of product candidate involved in development for the treatment of haematological malignancies and solid tumours. Autolus Therapeutics plc is based in London, United Kingdom.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.